Prokaryotic expression method of trigger factor fused B7H3
Through the fusion of the trigger factor TF and B7H3 protein and the prokaryotic expression system of insect baculovirus, the problem of low expression efficiency of B7H3 protein in the prokaryotic system was solved, and high purity and high uniformity B7H3 protein was obtained, which promoted its structural and functional research.
Patent Information
- Application Number
- CN202410998552.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-24
- Publication Date
- 2024-11-05
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The prior art is difficult to efficiently express high-purity and high uniformity B7H3 protein in prokaryotic systems, and its three-dimensional structure analysis is limited, hindering the progress of drug research and development.
The trigger factor TF is fused with B7H3 protein, combined with insect baculovirus and prokaryotic expression systems, and the expression of high-yield and high-purity B7H3 protein is achieved by screening tags and expression conditions, and the tag is removed by TEV enzyme cleavage and purified.
The successful acquisition of B7H3 protein with high purity, high uniformity and high activity has promoted its crystal structure and function research and provided a reliable foundation for drug research and development.
Smart Images

Figure CN118894946A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to a prokaryotic expression method of a trigger factor fused to a B7H3 protein. Background Art
[0002] The B7 family is an immunoglobulin superfamily. Currently, 11 B7 family proteins have been discovered, all of which are closely related to tumor development. For example, B7-H3, as a co-stimulatory factor, has a co-stimulatory effect on T cells and induces cellular immunity.
[0003] Human B7-H3 (CD276) is a member of the B7 superfamily and a type I transmembrane glycoprotein. Immunohistochemical (IHC) analysis of a large number of normal tissues showed that B7H3 was only lowly expressed in a few tissues, or even undetectable, with only weak cytoplasmic staining in salivary gland acinar cells, gastric epithelial cells, and adrenal cells. The lowest expression frequency of B7H3 was in renal cell carcinoma and hematological malignancies (33.0% and 36.7%, respectively, p<0.001), while the expression frequency of B7H3 in all other solid cancer types was at least 52.3%. Among gastrointestinal tumors, hepatocellular carcinoma had the highest expression frequency of B7-H3 (91.8%), and gastric cancer had the lowest expression frequency of B7-H3 (58.0%). Among genitourinary malignancies, renal cell carcinoma had the lowest expression frequency of B7-H3, while ovarian cancer had the highest expression frequency of B7-H3 (88.3%). Overexpression of B7H3 in tumor tissues is often associated with poor prognosis and shorter overall survival and progression-free survival. B7H3 can not only promote the immune escape of tumor cells by suppressing the immune system, but also mediate tumor metastasis, drug resistance, and angiogenesis through some non-immune pathways, thereby promoting cancer progression. Currently, more than 90 clinical trials have been or are testing the safety and effectiveness of immunotherapy strategies such as B7H3-targeted antibodies, bispecific antibodies, ADCs, and CAR-T.
[0004] However, the three-dimensional structure of B7H3 protein has not been resolved so far and drug development is quite challenging, which seriously hinders people's understanding of the function of B7H3 protein and structure-based drug development. The first key difficulty in three-dimensional structure analysis is to obtain high-quality (high uniformity, high purity) B7H3 protein. Unfortunately, B7H3 protein is currently only expressed in very low amounts in mammalian expression systems, and this method is expensive, cumbersome to operate, and has too many protein glycosylation modification sites (glycosylated proteins usually produce poorly diffracting crystals or are completely non-crystallizable), which seriously hinders B7H3 crystal screening.
[0005] B7-H3 is mainly expressed in the form of inclusion bodies in prokaryotic systems, which cannot form a correct three-dimensional structure and often do not have biological activity. Therefore, it is extremely important to explore the "low-cost, simple process, and high-yield" expression method of B7H3 protein, which is expected to promote researchers' research on the crystal structure, function and drug of B7H3 protein. Summary of the invention
[0006] To address the above-mentioned deficiencies, the present invention screened three fusion tags (histidine 6×His-tag, maltose binding protein MBP-tag, trigger factor TF-tag) and two expression systems (insect baculovirus and prokaryotic expression system), and explored and obtained the optimal expression method of B7H3 protein with low cost, high purity and high uniformity.
[0007] Specifically, the first aspect of the present invention provides a B7H3 fusion protein, which comprises a B7H3 protein and a trigger factor TF.
[0008] In certain embodiments, the trigger factor TF is located at the N-terminus or C-terminus of the B7H3 protein.
[0009] In some embodiments, the trigger factor TF and the B7H3 protein are directly or indirectly connected. In some embodiments, the junction between the trigger factor TF and the B7H3 protein contains a cleavable sequence.
[0010] In certain embodiments, the cleavable sequence is an enzyme cleavage site; preferably, the enzyme cleavage site is a TEV enzyme cleavage site.
[0011] In certain embodiments, the B7H3 protein comprises the amino acid sequence shown in SEQ ID NO:1, and / or the TF comprises the amino acid sequence shown in SEQ ID NO:2.
[0012] In certain embodiments, the fusion protein comprises the amino acid sequence shown in SEQ ID NO: 6 or 7.
[0013] The second aspect of the present invention provides a nucleic acid encoding the fusion protein described in the first aspect of the present invention.
[0014] In certain embodiments, the nucleic acid comprises a nucleotide sequence as shown in SEQ ID NO: 13-14 or a nucleotide sequence having 90% or more identity with SEQ ID NO: 13-14 and encoding an amino acid sequence as shown in SEQ ID NO: 6 or 7.
[0015] The third aspect of the present invention provides a vector, which comprises the nucleic acid described in the second aspect of the present invention; preferably, the vector is a prokaryotic expression vector.
[0016] The fourth aspect of the present invention provides a host cell, which comprises the nucleic acid described in the second aspect of the present invention or the vector described in the third aspect of the present invention; preferably, the host cell is a prokaryotic cell.
[0017] The fifth aspect of the present invention provides a method for expressing the fusion protein described in the first aspect of the present invention, wherein the method utilizes the host cell described in the fourth aspect of the present invention to express the fusion protein.
[0018] In certain embodiments, the method further comprises the steps of TF tag removal and B7H3 purification after the expression of the fusion protein.
[0019] In certain embodiments, an endonuclease is used to perform enzymatic removal of TF; preferably, the endonuclease is TEV enzyme; more preferably, the conditions of the enzymatic reaction are selected from any one or more combinations of the following 1) to 5): 1) the ratio of TEV to target protein TF-B7H3 is about 1:100, 2) the enzymatic cleavage time is about 10 h, 3) the enzymatic cleavage temperature is about 16°C, 4) the reducing agent TCEP content is about 2 mM, 5) the enzymatic cleavage buffer contains about 25 mM Tris pH 8.0, about 150 mM NaCl and about 5% glycerol.
[0020] In certain embodiments, after TF excision, TF is further removed by inverted nickel column for purification.
[0021] Compared with the prior art, the present invention has the following beneficial effects:
[0022] The present invention fused B7H3 with different tag proteins and performed protein expression screening at both the prokaryotic and eukaryotic levels. The fusion trigger factor TF-B7H3 protein was successfully screened out, which can be expressed in high yield in the prokaryotic expression system. The B7H3 protein purification conditions were obtained through system optimization, and then the high-purity, high-uniformity and high-activity B7H3 protein was obtained, which laid a solid foundation for promoting the crystal structure and function research of the B7H3 protein. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Other features, objects and advantages of the present invention will become more apparent from the detailed description of non-limiting embodiments made with reference to the following drawings:
[0024] Figure 1 (A) B7H3-His plasmid map; (B) B7H3-His nickel affinity chromatography SDS-PAGE results; (C) B7H3-MBP plasmid map; (D) B7H3-MBP nickel affinity chromatography SDS-PAGE results.
[0025] Figure 2(A) B7H3-pFastBac1 plasmid map; (B) Nickel affinity chromatography SDS-PAGE results of B7H3-pFastBac1 protein after SF9 cells were infected for 72 hours; (C) Nickel affinity chromatography SDS-PAGE results of B7H3-pFastBac1 protein after High Five cells were infected for 48 hours; (D) Nickel affinity chromatography SDS-PAGE results of B7H3-pFastBac1 protein after High Five cells were infected for 72 hours.
[0026] Figure 3 (A) Plasmid map of pCold-TF-B7H3; (B) Nickel affinity chromatography SDS-PAGE results of TF-B7H3.
[0027] Figure 4 (A) SEC results of TF-B7H3 protein; (B) SDS-PAGE results of TF-B7H3 protein.
[0028] Figure 5 (A) SEC results of B7H3 protein; (B) SDS-PAGE results of B7H3 protein; (C) ELISA to detect the binding ability of B7H3 protein with its antibody. DETAILED DESCRIPTION
[0029] In order to make the purpose, technical solution and advantages of the embodiment of the present invention clearer, the technical solution of the embodiment of the present invention will be clearly and completely described below in conjunction with the accompanying drawings of the embodiment of the present invention. Obviously, the described embodiment is a part of the embodiment of the present invention, not all of the embodiments. Based on the described embodiment of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0030] As used in the present invention, the term "trigger factor", also known as "Trigger Factor" or "TF", is a conserved bacterial molecular chaperone, a protein belonging to the FKBP506 family, and a component of protein export. It has a dual role: ① As a chaperone molecule, it interacts with the nascent polypeptide immediately after the appearance of the ribosome, maintains the nascent polypeptide in an open conformation, and promotes the correct folding of complex proteins; ② As a peptidyl-prolyl cis-trans isomerase, it efficiently catalyzes the isomerization of the prolyl peptide bond, further improving the conformational landscape of emerging proteins.
[0031] Unless otherwise defined, technical or scientific terms used herein shall have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs.
[0032] Example 1 Prokaryotic Expression of B7H3-His and B7H3-MBP
[0033] The plasmid B7H3-His (molecular weight 48.9 kDa, Figure 1 A, Table 4) and fused the maltose binding protein MBP to the N-terminus of B7H3 to form a plasmid with a structure of His-MBP-B7H3 (abbreviated as: B7H3-MBP, Figure 1 C, Table 4), and its molecular weight is approximately 91 kDa.
[0034] The steps of expressing and purifying B7H3 using the E. coli prokaryotic system are as follows:
[0035] 1) Prepare kanamycin sulfate solution: Take 2.5 g of kanamycin, add ultrapure water to dissolve, dilute to 50 mL (final concentration 50 mg / mL), and then filter with a 0.22 μm filter membrane on an ultra-clean bench for sterilization.
[0036] 2) Preparation of antibiotic-containing solid culture medium: add 0.1% kanamycin to sterilized 2YT medium (1.6% tryptone, 1% yeast extract, 0.5% NaCl) to prepare a kanamycin-resistant solid culture medium; add 0.1% chloramphenicol and 0.1% kanamycin to prepare a kanamycin-resistant culture medium.
[0037] 3) Add 1 μL of B7H3-His and B7H3-MBP plasmids to 100 μL of E. coli BL21 (DE3) competent cells and incubate on ice for 30 minutes;
[0038] 4) Heat shock the E. coli BL21 (DE3) competent cells after ice bath at 42°C for 60 seconds, and then cool them on ice for 2 minutes.
[0039] 5) Add 450 μL of sterilized LB medium into the clean bench and then culture at 37°C with a shaker at 200 rpm for 60 min.
[0040] 6) In the clean bench, take 100 μL of culture and drop it onto the solid LB culture dish, spread it evenly with a sterile coating stick, and place it in a 37°C constant temperature incubator for overnight culture.
[0041] 7) In a clean bench, pick a single clone and place it in 100 mL of sterile liquid LB medium. Incubate the culture overnight at 37°C and 200 rpm in a shaking incubator.
[0042] 8) Expansion and preservation: Take 10-20 mL of overnight cultured bacterial solution and add it to 1 L of sterile LB medium, then add 1 mL of kanamycin and culture on a shaker at 37°C. Take another 800 μL of bacterial solution and add 200 μL of 50% sterile glycerol, mix and store at -80°C.
[0043] 9) Preparation of inducer IPTG (isopropylthiogalactoside): Take 23.830 g of IPTG and dissolve it in ultrapure water, make the volume to 100 mL, then filter and sterilize it with a 0.22 μm filter membrane on an ultraclean workbench, and prepare 1 M IPTG for use.
[0044] 10) Induce protein expression: After the OD600 value of the bacterial solution reaches 0.6-0.8, the shaking temperature is lowered to 16°C and 50 μL IPTG solution (final concentration 0.05 mM) is added to the bacterial solution to induce protein expression for 16-20 hours.
[0045] 11) Preparation of buffer for purification of B7H3 protein
[0046] Buffer-A: 20mM Tris, 5000mM NaCl, pH8.0
[0047] Buffer-B: 20mM Tris, 5000mM NaCl, 500mM imidazole, pH8.0.
[0048] 12) Harvesting bacteria: Add the bacterial solution after overnight induction expression into a centrifuge bucket, centrifuge at 4000 rpm for 15 min, discard the supernatant, and resuspend the precipitate in buffer-A.
[0049] 13) Bacterial disruption: The collected bacterial resuspension was disrupted with a low-temperature high-pressure cell disruptor, and 20 μL of the disrupted bacteria was taken to obtain Bacterium Lysates for later use;
[0050] 14) High-speed centrifugation: Add the disrupted bacterial solution into an ultracentrifuge tube and centrifuge at 15,000 rpm for 30 min to separate the supernatant and precipitate, and take 20 μL of each sample for later use.
[0051] 15) Equilibration of the nickel column: Wash the nickel column with buffer-B for 10 column volumes (CV) to ensure that the nickel column is clean; wash with pure water for 10 CV to flush out buffer-B; and equilibrate the nickel column with 10 CV buffer-A.
[0052] 16) Protein nickel column affinity chromatography purification: The supernatant solution and the balanced nickel column filler were incubated in a 4°C refrigerator with slow stirring at a uniform speed for 1-2 h, and then all the solution was discharged and the nickel column was rinsed with buffer-A, and 20 μL of the effluent (FT) was collected for later use; 200 mL of a mixed solution of buffer-A:buffer-B=49:1 (10 mM imidazole) was used to rinse to remove non-specifically adsorbed impurities, and 20 μL of washing solution (Wsah1) was taken for later use; 200 mL of a mixed solution of buffer-A:buffer-B=48:2 (20 mM imidazole) was used to rinse to remove non-specifically adsorbed impurities, and 20 μL of washing solution (Wsah2) was taken for later use; finally, the target protein was eluted with buffer-A:buffer-B=1:1 (250 mM imidazole) to obtain a target protein solution (Elution) and 20 μL of it was taken for later use.
[0053] 17) Size Exclusion Chromatography (SEC): The protein solution obtained by nickel column affinity chromatography is concentrated and further purified by SEC chromatography column. The operation steps are as follows:
[0054] a) Buffer-SEC: 150 mM NaCl, 20 mM HEPES, pH 7.5, 5% glycerol. After the buffer is prepared, it is filtered with a 0.22 μm filter membrane for later use. Before use, 0.1% reducing agent TCEP (2 mM) is added.
[0055] b) Protein sample preparation: The protein sample was concentrated to a concentration of 20 mg / mL using a concentrator tube, and centrifuged at 4° C., 12,000 rpm, for 10 min to remove solid particles in the protein sample solution;
[0056] c) SEC column cleaning: Wash the pump with ultrapure water to fill the pump with ultrapure water, then set the system flow rate to 0.8 mL / min, control the pressure to Δ pressure 3.0 MPa, and install and clean the column according to the column instructions;
[0057] d) Balancing the chromatography column: Place the chromatography column pump head into Buffer SEC, wash the pump first, fill the pump cavity with Buffer SEC, and then balance the chromatography column with Buffer SEC;
[0058] e) Loading the sample: After the chromatography column is balanced, clean the loading loop and inject the protein sample into the loading loop.
[0059] f) Elution of the target protein: after the target protein peaks (ultraviolet absorption peak), collect the target protein solution.
[0060] g) Collect protein samples from all steps and identify and evaluate them using SDS-PAGE.
[0061] The results are as follows Figure 1 As shown, B7H3-His was not expressed in this strain, and MBP failed to help the B7H3 protein fold correctly and increase solubility. Traditional solubility-promoting tags could not enhance the expression of B7H3 protein in the prokaryotic expression system, and new methods needed to be explored.
[0062] Example 2 Bac-to-Bac Baculovirus Expression System for Eukaryotic Expression of B7H3 Protein
[0063] The insect baculovirus expression system is a high-yield eukaryotic gene expression system with a large capacity, the ability to express multiple foreign genes simultaneously, a strong promoter, an easily identifiable marker, and a high rate of correct protein folding. In view of this, we attempted to express B7H3 protein in the insect baculovirus expression system. First, we constructed a B7H3-pFastBac1 recombinant plasmid (molecular weight 48.9 kDa, Figure 2 A, Table 4). Subsequently, the recombinant protein was expressed using the Bac-to-Bac baculovirus expression system. Among them, the human recombinant B7H3 gene was codon-optimized for the insect expression system. The B7H3-pFastBac1 recombinant plasmid was synthesized by Sangon Biotech (Shanghai) Co., Ltd.
[0064] Expression steps of human recombinant B7H3 protein:
[0065] 1. Construction and identification of recombinant baculovirus shuttle vector reBacmid-B7H3
[0066] a) Transformation: 10 ng of pFastBac1 plasmid was added to 20 μL of commercial DH10bac competent cells, incubated on ice for 30 min, heat-shocked at 42°C for 45 s, incubated on ice for 2 min, and then added with 200 μL of LB medium. The cells were cultured at 37°C and 220 rpm with shaking for 4 h.
[0067] b) Take 2 μL of the above liquid and mix it evenly with 100 μL LB medium, 100 μL X-gal solution and 2 μL IPTG solution. Take 50 μL of the mixture and spread it on an agar plate (containing 50 μg / mL kanamycin, 10 μg / mL tetracycline and 7 μg / mL gentamicin). Incubate at 37°C in the dark for 72 h until blue-white spots are clearly visible.
[0068] c) Extraction of reBacmid-B7H3: Pick white spots and place them into 5 mL of LB medium containing antibiotics (kanamycin 50 μg / mL, tetracycline 10 μg / mL, gentamicin 7 μg / mL), culture at 37°C and 220 rpm with shaking for about 16 h, and then perform reBacmid extraction according to a commercial kit (TIANGEN, catalog number DP304).
[0069] d) PCR analysis of recombinant bacmid DNA was performed using universal primers for Bac-to-Bac baculovirus vector (M13-F: TATTCCGGATTATTCATACC (SEQ ID NO: 16); M13-R: ACAAATGTGGTATGGCTGA (SEQ ID NO: 17)). The PCR reaction system is shown in Table 1:
[0070] Table 1 PCR reaction system of recombinant bacmid DNA
[0071] Total volume 10μL 2×Phanta Flash Master Mix 5μL M13-F 1μL M13-R 1μL Recombinant baculovirus plasmid DNA 1μL dd H2O 2μL
[0072] The PCR reaction was carried out under the following conditions: 98°C for 30 s, 1 cycle; 98°C for 10 s, 58°C for 5 s, 72°C for 30 s, for a total of 35 cycles; extension at 72°C for 2 min; and finally storage at 16°C.
[0073] 2. Expression of human recombinant B7H3 protein in insect cells
[0074] a) Preparation of transfection complex: Preparation of transfection complex A solution: 10 μg reBacmid-B7H3 + SF9 culture medium = 100 μL; B solution: 8 μL transfection reagent (LipoInsect TM , C0551-1, purchased from Bio-Tech Biotech Co., Ltd.) + 92 μL SF9 medium = 100 μL, mix A and B to form a transfection complex, and let stand for 30 min;
[0075] b) Each well of a six-well plate is plated with 0.8×10 6 SF9 cells, wait until the cells adhere to the bottom (about 15 minutes), then gently add all the transfection complexes to the six-well plate and place at 27℃ for 4 hours;
[0076] c) After 4 hours, remove the supernatant and gently add 3 mL of fresh SF9 medium along the well wall;
[0077] d) Place at 27°C for 4 days, then aspirate the supernatant, centrifuge at 800 g for 3 min, collect the supernatant, and add 4% serum, which is the P1 virus;
[0078] e) Take 1 mL of P1 virus and add it to 50 ml of SF9 cells (density 2×10 6 ) and cultured with shaking at 27°C and 110 rpm for 7 days. The remaining P1 was stored at 4°C. After 7 days, the supernatant was collected by centrifugation at 2000 rpm for 15 min and 4% serum was added. This is the P2 virus.
[0079] f) Take 1 mL of P2 virus and add it to 50 ml of SF9 cells (density 2×10 6) and cultured at 27°C, 110 rpm, shaking for 1 day. The remaining P2 was stored at 4°C. After 7 days, the supernatant was collected by centrifugation at 2000 rpm for 15 min, 4% serum was added, and the supernatant was stored at 4°C. This is the P3 virus;
[0080] g) The conditions for expressing human recombinant B7H3 protein by infecting cells with P3 virus were optimized. The optimized conditions are shown in Table 2.
[0081] Table 2. Conditions for expressing human recombinant B7H3 protein
[0082] project content Virus infection rate 1:300(v / v) time 48h, 72h Cell lines SF9, High Five
[0083] After expressing the protein under each condition, similar steps were performed for prokaryotic expression, including cell disruption, centrifugation to separate the supernatant, loading on a nickel affinity column, washing the impurities with different imidazoles, preferably eluting the target protein with high concentrations of imidazole. At the same time, samples were taken in sequence from each step (cell lysates, precipitate, supermatant, effluent FT, wash 1-2-3, and elution) for SDS-PAGE detection to compare the protein expression under different conditions. The results are shown in the figure. Figure 2 As shown, no matter whether SF9 cells or High Five cells were used, no target band was found in the cell lysate or precipitate regardless of whether the virus was infected for 48 hours or 72 hours, so the target protein could not be obtained through nickel column affinity chromatography.
[0084] Example 3 Prokaryotic Expression of TF-B7H3 Fusion Protein
[0085] In order to further explore the way to obtain high-quality B7H3 protein, B7H3 was fused with the trigger factor TF, and the prokaryotic expression system was used for expression screening again. First, a B7H3 plasmid with His, TEV restriction sites and TF protein at the N-terminus was constructed (pCold-TF-B7H3, Figure 3 A, Table 4), and then transformed into E. coli BL21 (DE3) cells for expression (see Example 1 for specific methods). The expression results are shown in Figure 3As shown in B, TF-B7H3 (theoretical molecular weight of protein 97.7kDa) bands were clearly observed in the supernatant and precipitate. When the protein was eluted with different imidazole concentrations, it was found that 20mM imidazole (50mM IM) could elute some non-specific binding proteins, 50mM imidazole (50mM IM) could elute TF-B7H3 protein but the purity was low. TF-B7H3 protein bands were clearly observed in the 250mM imidazole eluate, and the purity was >85%. Statistical results showed that the initial purification yield of TF-B7H3 in E.coli BL21 (DE3) cells reached 25mg / L.
[0086] In order to further evaluate the purity and homogeneity of TF-B7H3 protein expressed by pCold-TF-B7H3 plasmid in E. coli BL21 (DE3) cells, gel filtration chromatography analysis was carried out. The results showed that the TF-B7H3 protein expressed by this system showed only a single 280UV absorption peak in gel filtration chromatography, indicating that the protein obtained by this expression system is of high homogeneity ( Figure 4 A).
[0087] In order to further identify the purity of TF-B7H3 protein, SDS-PAGE identification was performed, and the analysis showed that the purity of TF-B7H3 protein expressed and purified by this method was >95% ( Figure 4 B), in line with the research needs of crystal structure, function, etc.
[0088] Example 4 Removal of TF from fusion protein
[0089] In order to further obtain high-quality B7H3 protein, TF tag protein was removed by TEV digestion, and TF tag protein was further removed by reverse hanging nickel column. However, B7H3 protein precipitated rapidly after TF removal. In order to obtain high-quality B7H3 protein, large-scale purification conditions were subsequently optimized. Using EXpasy website analysis (Table 3), it was determined that the theoretical molecular weight of B7H3 after tag removal was 48.3kDa, the isoelectric point pI was 4.93 (acidic protein), and the molecule contained 42 negatively charged amino acids (Asp+Glu), 26 positively charged amino acids (Arg+Lys) and 9 cysteines. The protein instability index (II) was calculated to be 38.59 (defined as proteins <40 are predicted to be stable), and it was classified as a stable protein. The lipophilic index analysis showed that the lipophilic index of B7H3 protein was 84.77, which was a lipophilic protein, and its average hydrophilicity (GRAVY) was -0.083 (defined as the ratio of the sum of the hydrophilicity values of all amino acids in the sequence to the number of amino acids. The larger the negative value, the better the hydrophilicity, and the larger the positive value, the stronger the hydrophobicity). By comparing the parameters related to TF-B7H3 protein, it was found that the average hydrophilicity of the two was quite different. In view of this, it is speculated that the precipitation of B7H3 protein is not caused by its instability, but by its general hydrophilicity or inappropriate purification conditions.
[0090] Table 3 Analysis of properties of TF-B7H3 and B7H3 proteins
[0091]
[0092] To this end, the TF excision conditions were optimized. ① In view of the fact that the fat solubility index of B7H3 protein was 84.77 and its heat resistance was good, the enzyme cleavage temperature was changed from 4°C to 16°C, and the enzyme cleavage time was shortened from 16 hours to 10 hours to reduce the precipitation of B7H3 protein due to long time and low temperature; ② The salt concentration of the enzyme cleavage solution was reduced to 150mM to prevent high concentration salt from destroying the hydration membrane around the protein, causing protein aggregation and precipitation; ③ The reducing agent β-ME was replaced with TCEP to achieve long-term reduction during the enzyme cleavage process. ④ 5% glycerol was added to various buffer solutions as a dispersant to prevent protein molecules from contacting and colliding and reduce protein aggregation.
[0093] Through system optimization, the optimal TF tag removal conditions were finally determined: TEV to target protein TF-B7H3 ratio 1:100, enzyme cleavage time 10h, enzyme cleavage temperature 16℃, TCEP content 2mM, enzyme cleavage buffer 25mM Tris pH8.0 150mM NaCl 5% glycerol. The results are as follows Figure 5As shown in A, the TF tag was successfully removed to obtain highly homogeneous B7H3 protein. SDS-PAGE results showed that the purity of B7H3 protein reached >95% ( Figure 5 B) and the yield reached 10 mg / L. To further evaluate the activity of B7H3 protein, commercial B7H3 antibody (Abcam, #ab134161) and ELISA were used to detect the activity of the protein purified by this system.
[0094] The ELISA steps are as follows: the purified B7H3 protein is coated on the ELISA plate at 5 μg / mL, 100 μL per well, and incubated in a constant temperature incubator at 37°C for 2 hours; 100 μL of 5% BSA solution is added to each well for blocking for 1 hour to avoid nonspecific binding; the antibody concentration starts at 10 μg / mL and is diluted 2-fold; the antibody is added to the ELISA plate and incubated in a constant temperature incubator at 37°C for 1 hour; HRP-labeled goat anti-rabbit secondary antibody (1:5000, Thermo Fisher Scientific, catalog#31460.) is added and incubated in a constant temperature incubator at 37°C for 1 hour; the above liquids are discarded, 100 μL of ELISA colorimetric solution is added to each well, and incubated at 25°C in the dark for 20 minutes; 50 μL of ELISA stop solution is added to each well, and the OD450 value is read and calculated at 450 nm by an enzyme reader.
[0095] The results are as follows Figure 5 As shown in Figure C, B7H3 protein can effectively bind to B7H3 monoclonal antibody with an EC50 of 94.9 ng / mL. Endotoxin is a product of the cell wall of Gram-negative bacteria. If endotoxin is not removed during protein purification, it may affect subsequent in vitro and in vivo functional studies of B7H3 protein. In view of this, the endotoxin content of the B7H3 protein expression and purification system constructed by the present invention was detected using the horseshoe crab reagent method. The results showed that the endotoxin level of the B7H3 protein obtained by this method was <0.1EU / μg, which is suitable for in vitro and in vivo functional studies.
[0096] The amino acid and nucleotide sequences of B7H3, fusion tags and fusion proteins involved in the above Examples 1-4 are shown in Table 4 below.
[0097] Table 4 Sequences of fusion proteins and their components
[0098]
[0099]
[0100]
[0101]
[0102]
[0103]
[0104]
[0105] Note: The sequences represented by each SEQ ID NO in Table 4 do not include the content marked in brackets; unless otherwise specified, each SEQ ID NO represents the full-length sequence listed in each cell. Special note: SEQ ID NO: 6 and SEQ ID NO: 13 represent the sequences in italics in the corresponding cells.
[0106] The above shows and describes the basic principles and main features of the present invention and the advantages of the present invention. It is obvious to those skilled in the art that the present invention is not limited to the details of the above exemplary embodiments, and the present invention can be implemented in other specific forms without departing from the spirit or basic features of the present invention. Therefore, no matter from which point of view, the embodiments should be regarded as exemplary and non-restrictive. The scope of the present invention is defined by the attached claims rather than the above description, and it is intended that all changes falling within the meaning and scope of the equivalent elements of the claims are included in the present invention. Any figure mark in the claims should not be regarded as limiting the claims involved.
[0107] In addition, it should be understood that although this specification is described in terms of implementation methods, not every implementation method contains only one independent technical solution. This description method of the specification is only for the sake of clarity. Those skilled in the art should regard the specification as a whole. The technical solutions in each embodiment can also be appropriately combined to form other implementation methods that can be understood by those skilled in the art.
Claims
1. B7H3 fusion protein, It is characterized in that The fusion protein comprises B7H3 protein and trigger factor TF.
2. The fusion protein according to claim 1 or 2, It is characterized in that The trigger factor TF is located at the N-terminus or C-terminus of the B7H3 protein; the trigger factor TF and the B7H3 protein are directly or indirectly connected; preferably, the connection between the trigger factor TF and the B7H3 protein contains a cleavable sequence.
3. The fusion protein according to claim 3, It is characterized in that The cleavable sequence is an enzyme cleavage site; preferably, the enzyme cleavage site is a TEV enzyme cleavage site.
4. The fusion protein according to any one of claims 1 to 3, It is characterized in that The B7H3 protein comprises the amino acid sequence shown in SEQ ID NO: 1, and / or the TF comprises the amino acid sequence shown in SEQ ID NO:
2.
5. The fusion protein according to claim 4, It is characterized in that The fusion protein comprises the amino acid sequence shown in SEQ ID NO: 6 or 7.
6. A nucleic acid encoding the fusion protein according to any one of claims 1 to 3; preferably, the nucleic acid comprises the nucleotide sequence shown in SEQ ID NO: 13-14 or a nucleotide sequence having more than 90% identity with SEQ ID NO: 13-14 and encoding the amino acid sequence shown in SEQ ID NO: 6 or 7.
7. A vector comprising the nucleic acid of claim 6; preferably, the vector is a prokaryotic expression vector.
8. A host cell comprising the nucleic acid of claim 6 or the vector of claim 7; preferably, the host cell is a prokaryotic cell.
9. A method for expressing the fusion protein according to any one of claims 1 to 5, It is characterized in that The method utilizes the host cell of claim 8 to express the fusion protein, and preferably, further comprises the steps of TF tag removal and B7H3 purification after the fusion protein is expressed.
10. The method according to claim 9, It is characterized in that An endonuclease is used to perform enzymatic cleavage and removal of TF; preferably, the endonuclease is TEV enzyme; more preferably, the conditions of the enzymatic cleavage reaction are selected from any one or more combinations of the following 1) to 5): 1) the ratio of TEV to target protein TF-B7H3 is about 1:100, 2) the enzymatic cleavage time is about 10 h, 3) the enzymatic cleavage temperature is about 16°C, 4) the reducing agent TCEP content is about 2 mM, 5) the enzymatic cleavage buffer contains about 25 mM Tris pH 8.0, 150 mM NaCl and 5% glycerol.
Citation Information
Patent Citations
Method for expressing and purifying soluble dermatophagoides pteronyssinus major allergen Der p 2 protein
CN106282213A
Anti-B7-H3 antibody, preparation method thereof, conjugate and application thereof
CN110305213A
Hybridoma cell strain capable of generating anti-B7H3 monoclonal antibody and application of hybridoma cell strain
CN117025547A
Expression and purification method of immune checkpoint protein B7-H3
CN118271421A
B7-h3 targeting fusion proteins and methods of use thereof
WO2023043955A1
